NEW YORK (GenomeWeb) – Next-generation sequencing-based diagnostics firm Guardant Health today announced it raised $30 million in a Series B financing.

Khosla Ventures led the round and was joined by existing investor Sequoia Capital and new investor Pejman Mar Ventures.

The financing "will allow Guardant Health to accelerate the expansion of its commercial operations to support growing demand and ensure a distinctively high level of service for our physicians and patients," Guardant CEO and Co-Founder Helmy Eltoukhy said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: factors affecting the success of whole-genome sequencing for routine clinical diagnosis, and more.

A large meta-analysis from an international team reports that nature and nurture have about an equal overall influence on human traits.

The Lasker Foundation's Claire Pomeroy laments the state of NIH funding at Forbes.

Social media is changing how scientists discuss research, as tweets from University of Chicago's Yoav Gilad about a Mouse ENCODE paper have shown, Nature reports.